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Geographic Variation in Health Service Use and Perceived Access Barriers for 
Australian Adults with Chronic Non-Cancer Pain Receiving Opioid Therapy 
Abstract 
Objective. Rates of chronic non-cancer pain are increasing worldwide, with concerns regarding poorer 
access to specialist treatment services in remote areas. The current study comprised the first in-depth 
examination of use and barriers to access of health services in Australia according to remoteness. 
Methods. A cohort of Australian adults prescribed pharmaceutical opioids for chronic non-cancer pain (n 
= 1,235) were interviewed between August 2012 and April 2014, and grouped into 'major city' (49%), 'inner 
regional' (37%), and 'outer regional/remote' (14%) according to the Australian Standard Geographical 
Classification based on postcode. Multinomial logistic regression analyses were conducted to determine 
geographical differences in socio-demographic and clinical characteristics, health service use, and 
perceived barriers to health service access. Results. The 'inner regional group' and 'outer regional/remote 
group' were more likely to be male (relative risk ratio (RRR)=1.38,95%CI 1.08-1.77 and RRR = 1.60, 95%CI 
1.14-2.24) and have no private health insurance (RRR = 1.53, 95%CI 1.19-1.97 and RRR = 1.65, 95%CI 
1.16-2.37) than the 'major city group' (49%). However, the 'inner regional group' reported lower pain 
severity and better mental health relative to the 'major city group' = 0.92, 95%CI 0.86-0.98 and RRR = 1.02, 
95%CI 1.01-1.03, respectively). Although rates of health service access were generally similar, the 'outer 
regional/remote group' were more likely to report client-practitioner communication problems (RRR = 
1.57, 95%CI 1.03-2.37), difficulties accessing specialists (RRR = 1.56, 95%CI 1.01-2.39), and perception of 
practitioner lack of confidence in prescribing pain medication (RRR = 1.73, 1.14-2.62), relative to both 
groups. Conclusion. Perceived communication, access, and financial barriers to healthcare indicate the 
need for increased efforts to address geographic inequality in pain treatment. 
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Abstract 27 
Objective: Rates of chronic non-cancer pain are increasing worldwide, with concerns 28 
regarding poorer access to specialist treatment services in remote areas. The current study 29 
comprised the first in-depth examination of use and barriers to access of health services in 30 
Australia according to remoteness.   31 
Methods: A cohort of Australian adults prescribed pharmaceutical opioids for chronic non-32 
cancer pain (n=1,235) were interviewed between August, 2012 and April, 2014, and grouped 33 
into ‘major city’ (49%), ‘inner regional’ (37%) and ‘outer regional/remote’ (14%) according 34 
to the Australian Standard Geographical Classification based on postcode.  Multinomial 35 
logistic regression analyses were conducted to determine geographical differences in socio-36 
demographic and clinical characteristics, health service use, and perceived barriers to health 37 
service access. 38 
Results: The ‘Inner Regional group’ and ‘Outer Regional/Remote group’ were more likely to 39 
be male (relative risk ratio (RRR)=1.38,95%CI 1.08-1.77 and RRR=1.60, 95%CI 1.14-2.24) 40 
and have no private health insurance (RRR=1.53, 95%CI 1.19-1.97 and RRR=1.65, 95%CI 41 
1.16-2.37) than the ‘Major City group’ (49%). However, the ‘Inner Regional group’ reported 42 
lower pain severity and better mental health relative to the ‘Major City group’ =0.92, 95%CI 43 
0.86-0.98 and RRR=1.02, 95%CI 1.01-1.03, respectively). Although rates of health service 44 
access were generally similar, the ‘Outer Regional/Remote group’ were more likely to report 45 
client-practitioner communication problems (RRR=1.57, 95%CI 1.03-2.37), difficulties 46 
accessing specialists (RRR=1.56, 95%CI 1.01-2.39), and perception of practitioner lack of 47 
confidence in prescribing pain medication (RRR=1.73, 1.14-2.62), relative to both groups.  48 
Conclusion: Perceived communication, access and financial barriers to health care indicate 49 
the need for increased efforts to address geographic inequality in pain treatment.  50 
Keywords: chronic pain; healthcare; treatment; remote; policy; opioids 51 
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Introduction 52 
 53 
 In Australia, chronic pain is estimated to affect nearly 20% of the adult population (2-5). 54 
Chronic non-cancer pain (CNCP) reduces quality of life and impairs physical functioning, 55 
sleep, mood, ability to work, and activities of daily living (e.g., walking, shopping) (6, 7), 56 
with an estimated cost of AUD$34 billion nationally per annum in Australia (4). Treatments 57 
that reduce pain severity and interference can mitigate some of these negative consequences 58 
and reduce health care, societal and economic burden (6). The use of opioid pharmacotherapy 59 
has increased in recent years, despite insufficient evidence for the effectiveness of long-term 60 
opioid treatment for CNCP (8). Australia’s consumption of opioid analgesics was ranked 10th 61 
globally in 2010, with higher rankings for specific analgesics (3rd and 5th for oxycodone and 62 
morphine) (9). Behavioural, psychological and non-opioid pharmacotherapy treatments are 63 
also available and demonstrate some efficacy in reducing pain (10-12). As such, current 64 
guidelines typically emphasise a multi-disciplinary approach to treatment (13).  65 
 66 
Despite the prevalence, recent data indicates that many people with CNCP are not able to 67 
access specialist care either in Australia nor internationally, with concern that access 68 
problems are amplified in remote geographical areas (14, 15). Higher rates of mortality and 69 
morbidity are typically evident for those living in remote areas of Australia relative to those 70 
living in urban areas (16). Whilst some self-report population-based studies show  similar 71 
rates of health service use across remoteness regions (17), analysis of routine administrative 72 
data suggests fewer general practitioners and specialists available per capita, and lower rates 73 
of health service use (with the notable exception of higher hospitalisation rates), in remote 74 
areas (16) . Strategic action plans emphasise addressing these inequalities through updated 75 
models of care and health service funding (15). To undertake such action, geographical 76 
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variation in the experience of CNCP and treatment service access need to be understood, and 77 
other factors which may impact on access (e.g., financial barriers, perceived quality of 78 
services and treatments, beliefs regarding effects of medications, strategies for coping, level 79 
of support) investigated. To date, such undertakings in Australia have generally been focused 80 
only on a small sample within a single geographic region, as in the qualitative study by 81 
Briggs et al. (18), who identified poor access to information and services and inadequate pain 82 
management training as primary barriers to health service access for fourteen participants 83 
with chronic low back pain in remote Western Australia.  84 
 85 
As such, the aims of this paper are to: 86 
 Compare the socio-demographic and clinical profile of a cohort of adults Australians 87 
with CNCP prescribed opioids by geographical remoteness classification (major 88 
cities, inner and outer regional, remote and very remote locations);  89 
 Compare treatment and health service access according to geographical remoteness 90 
classification amongst this cohort; and 91 
 Compare barriers to accessing treatment and services (e.g., financial considerations, 92 
access and beliefs) according to geographical remoteness classification amongst this 93 
cohort.   94 
 95 
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Methods 96 
Design  97 
The Pain and Opioids IN Treatment (POINT) study is a prospective cohort study of 1,514 98 
persons in Australia prescribed opioids for CNCP (for a full description of the cohort 99 
methodology, see Campbell et al. (19)). The data presented were collected via telephone 100 
interview with a researcher, a self-complete survey and medication diary at baseline (August 101 
2012 to April, 2014). The self-complete survey and medication diary were completed at 102 
home in the week following the telephone interview.  103 
 104 
Ethics 105 
The study was approved by the UNSW Human Research Ethics Committee (#HC12149). The 106 
study also received A1 National Pharmacy Guild Approval to approach pharmacists to assist 107 
with recruitment (#815). 108 
 109 
Eligibility Criteria 110 
Inclusion criteria comprised: 18 year of age or older, competent in English; without apparent 111 
memory or other cognitive impairment; living with CNCP (defined as pain present daily for a 112 
minimum of three months); and currently prescribed a strong opioid classified as Schedule 8 113 
of the Australian Uniform Scheduling of Medicines and Poisons (morphine, oxycodone, 114 
fentanyl, buprenorphine, methadone, hydromorphone, and codeine phosphate as a single 115 
ingredient) (20) and used this prescribed opioid for more than 6 weeks at the time of 116 
admission in the cohort. Exclusion criteria comprised cases where Schedule 8 opioids were 117 
prescribed for cancer pain or as opioid substitution therapy for heroin dependence. 118 
 119 
Participants and Procedures 120 
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From a database of 5,745 community pharmacies, 1,868 were willing to refer potentially 121 
eligible participants (19). In total, 35% of pharmacies across all states and territories in 122 
Australia agreed to participate. Of those potential participants who were referred (n=2,725), 123 
1,873 were eligible, and a total of 1,514 completed the baseline POINT study interview (201 124 
refused after being deemed eligible and 100 were unable to be contacted). Phone interviews 125 
were conducted by research assistants who had a minimum 3-year health or psychology 126 
degree. Interviewers had received training in the survey instrument and were provided 127 
glossaries of chronic pain medications and conditions. Participants were included in the 128 
analyses reported in this paper if they completed both the baseline telephone interview and 129 
the self-complete measures including the medication diary (n=1,243); a further eight 130 
participants were excluded as they did not provide their postcode (final sample n=1,235).   131 
 132 
Measures 133 
Full details of the measures administered in the study are reported elsewhere (19); brief 134 
summaries of measures used in the current analyses are provided below.  135 
 136 
Demographic and Clinical Characteristics  137 
In addition to demographics, participants reported lifetime pain conditions and pain duration. 138 
Participants also completed the Brief Pain Inventory short-form (BPI) (21), and current pain 139 
severity and pain interference sub-scores were calculated. Physical and mental health 140 
component scores from the SF-12 were calculated; scores were calculated according to 141 
standard algorithms, with higher scores indicating better health (22). Depression and 142 
generalised anxiety disorder were measured using the Patient Health Questionnaire (PHQ-9) 143 
and the Generalised Anxiety Disorder (GAD-7) modules of the Patient Health Questionnaire 144 
(23). Symptoms indicating moderate to severe depression were defined as a score of ≥10 on 145 
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the PHQ-9 (24), symptoms of moderate to severe anxiety were defined as a score of ≥10  on 146 
the GAD-7 (25). Post-traumatic stress disorder (PTSD) was measured using the Primary Care 147 
PTSD screen (PC-PTSD); a score ≥ 3 was considered indicative of PTSD (26). 148 
 149 
Treatment and Health Service Access 150 
Participants were asked about past month prescribed use of pharmaceutical opioids and 151 
duration of current continuous episode of opioid use. Oral morphine equivalent (OME) daily 152 
doses were estimated using available references (27) based on self-reported opioid use in a 153 
medication diary completed over a one week period (included in the self-complete 154 
questionnaire mailed to participants). Participants reported the number of times they had used 155 
certain health services (general practitioners, ambulance and emergency department services, 156 
and hospital day procedures) in the past month. Participants were also asked about past 157 
month use of health services directly related to pain, including physiotherapy, medical 158 
specialist services, mental health services (i.e., psychiatrist, psychologist, and counsellor); 159 
other physical therapies (i.e., massage, Osteopath, Yoga, Tai Chi, Feldenkrais, Pilates, 160 
Supervised Exercise, Tens Machine and Bowen Therapy) and complementary and alternative 161 
medicines (i.e., chiropractic services, support groups, acupuncture, vitamins and minerals). 162 
 163 
Barriers to Treatment 164 
Items assessing barriers to treatment were extracted from previous research (28), and then 165 
modified based on feedback from the study’s chief investigators and advisory committee. 166 
Participants were asked if they had ever experienced particular barriers (yes/no). Barriers 167 
included being unable to get to a pharmacy or doctor, being unable to access specialist 168 
advice, being unable to afford other types of medication and being unable to afford other 169 
treatments (e.g., counselling, physiotherapy, and chiropractor). 170 
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Medication Beliefs, Pain Self-Efficacy, Social Support and Alcohol and Other Drug Use 172 
Medication beliefs were assessed by two subscales of the Beliefs about Medications 173 
Questionnaire (BMQ) (29): the Specific-Necessity subscale, which assesses the participants’ 174 
beliefs about the necessity of their current medication, and the Specific-Concerns subscale 175 
which measures concerns about prescribed medication. Score range for each scale is 0-25, 176 
with higher scores reflecting stronger beliefs. The Pain Self-Efficacy Questionnaire (PSEQ) 177 
was administered to assess participants’ perceived capacity to perform activities (e.g., 178 
household chores) while in pain and without medication (30), with higher scores (range 0-60) 179 
reflecting higher self-efficacy beliefs.  The Medical Outcomes Survey (MOS) Social Support 180 
index assessed functional support from others; an average score was calculated (range 1-5), 181 
with higher scores indicating greater support. Past 12 month use of alcohol, tobacco, and 182 
cannabis was also assessed via single self-report items (yes/no).    183 
 184 
Data Analysis 185 
Participants were grouped by postcode in accordance with the 2006 edition of the Australian 186 
Standard Geographical Classification (ASGC) (31) and grouped into three categories based 187 
on remoteness of the community of residence: (i) major cities (‘Major City group’: 49%, 188 
n=608), (ii) inner regional communities (‘Inner Regional group’: 37%, n=451), and (iii) outer 189 
regional, remote and very remote communities (‘Outer Regional/Remote group’: 14%, 190 
n=176). Although this sample was not intended to be nationally representative, as of June 191 
2014, 71% of the Australian population resided in major cities, 18% in inner regional areas, 192 
and 11% resided in outer regional, remote and very remote locations (32). Participants were 193 
recruited from each state and territory in Australia (Queensland: 33%, n=408; New South 194 
Wales: 22% n=267; Victoria: 19%, n=234; South Australia: 14%, n=167; Western Australia: 195 
Geography, Healthcare and Chronic Pain 
7%, n=90; Tasmania: 4%, n=52; Australian Capital Territory: 1%, n=9; Northern Territory: 196 
1%, n=8). 197 
 198 
Data were analysed using multinomial logistic regression conducted in SPSS Statistics v21 199 
(33); the referent category was the ‘Major City group’. Results are presented as relative risk 200 
ratios (RRR; i.e., the probability of an outcome in one group relative to another). 201 
Additionally, relative risk ratios were calculated to compare the ‘Inner Regional group’ and 202 
‘Outer Regional/Remote group’ in regards to perceived barriers given that these outcomes 203 
comprised the primary focus of the study. Percentages with 95% confidence intervals 204 
(95%CI) are reported for categorical outcomes, means and standard deviations (M, SD) are 205 
reported where continuous data were normally distributed, and medians and inter-quartile 206 
ranges (M, IQR) are reported where continuous data show significant skew and/or kurtosis. 207 
Adjusted RRR were calculated for health service access; barriers to treatment; medication 208 
beliefs; pain self-efficacy; social support; and alcohol and other drug use outcomes. These 209 
analyses controlled for age and sex (identified from research showing differences in pain 210 
responses based on these characteristics; 34), low income (<AUD$400) and private health 211 
insurance, and demographic and clinical variables statistically significant in univariate 212 
analyses.  213 
 214 
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Results 215 
Sample Characteristics 216 
The sample (n=1,235) had a median age of 59 (IQR: 49-68) and over half (57%) were female 217 
(Table 1). The majority had not completed tertiary education (64%), reported income 218 
<AUD$400 (59%), and did not have private health insurance (63%), and nearly half (47%) 219 
were currently unemployed. The most common CNCP conditions reported by the sample 220 
were chronic neck/back problems (79%), followed by arthritis/rheumatism (68%), and 221 
frequent/severe headaches (45%) (Table 1). Participants reported being in pain for a median 222 
of 10 years and had been taking pharmaceutical opioids for CNCP for a median period of 4 223 
years.  224 
 225 
Differences by Geographical Remoteness 226 
Demographic Characteristics 227 
Compared to the ‘Major City group’, participants in the ‘Inner Regional group’ and ‘Outer 228 
Regional/Remote group’ had greater relative risk of being male and not have private health 229 
insurance (Table 1). Further, the ‘Inner Regional group’ also reported poorer educational 230 
attainment, and the Outer Regional/Remote group’ were more likely to be younger, than the 231 
‘Major City group’.  232 
***Table 1 approximately here*** 233 
 234 
Clinical Characteristics 235 
The duration of living with CNCP and the rate of various CNCP conditions were similar 236 
across the geographical remoteness groups (Table 1). The ‘Inner Regional group’ reported 237 
lower BPI Severity scores, had better mental functioning and wellbeing (as scored on the SF-238 
12), and tended to report lower relative risk of exceeding PHQ-9 and GAD-7 score cut-offs 239 
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indicative of current moderate-to-severe depression and anxiety respectively, compared to the 240 
‘Major City group’.  241 
 242 
Medication Use  243 
Univariate analyses showed that the groups were similar in regards to length of time in opioid 244 
treatment (4 years on average), median opioid dose, and in the distribution of persons 245 
receiving a high OME daily dose (15% of the sample ≥200mg/day) (Table 1). The ‘Inner 246 
Regional group’ had greater relative risk of currently using fentanyl and lower relative risk of 247 
using oxycodone and prescription codeine in the past month, and the ‘Outer Regional/Remote 248 
group’ had greater relative risk of using morphine in the past month, as compared to the 249 
‘Major City group’.  250 
 251 
Health Service Access  252 
The majority of the sample had seen a GP in the past month (95%) on a median of two 253 
occasions, with no significant difference between the geographical remoteness groups in the 254 
number of visits (Table 2). Rates of past month ambulance and emergency department 255 
access, and hospital-based day procedures were also similar across the remoteness groups; 256 
past month use was 7%, 12%, and 11% of the total sample for each service, respectively. As 257 
compared to the ‘Major City group’, the ‘Inner Regional group’ had a lower relative risk of 258 
accessing physiotherapy and mental health services for chronic pain in the past month; these 259 
associations were not statistically significant following multivariate analyses. The ‘Inner 260 
Regional group’ and ‘Outer Regional/Remote group’ had two- and three-fold increased 261 
relative risk of reporting past month use of other physical therapies as compared to the 262 
‘Major City group’ (9% and 15% versus 5%); these associations remained statistically 263 
Geography, Healthcare and Chronic Pain 
significant after adjusting for age, sex, income <AUD$400, private health insurance, tertiary 264 
education and BPI Severity score.  265 
***Table 2 approximately here*** 266 
 267 
Perceived Barriers to Health Service Access  268 
As compared to the ‘Major City group’, the ‘Outer Regional/Remote group’ had significantly 269 
a greater relative risk of reporting that they: i) felt their doctor was not confident in 270 
prescribing pharmaceutical opioids, ii) had communication difficulties with their doctor, iii) 271 
were unable to access specialist services, and iv) were unable to afford opioid medication 272 
(Table 2). After adjusting for age, sex, income <AUD$400, private health insurance, tertiary 273 
education and BPI Severity score, these associations remained significant with the exception 274 
of ‘being unable to afford opioid medication’. There were no significant differences between 275 
the ‘Major City group’ and the ‘Inner Regional group’ after adjustment for confounding 276 
variables.  277 
 278 
Calculation of relative risk (RR) to compare the ‘Inner Regional group’ and ‘Outer 279 
Regional/Remote group’ showed that the latter were more likely to report that that they: i) felt 280 
their doctor was not confident in prescribing pharmaceutical opioids (RR=1.24, 95%CI 1.07-281 
1.45), ii) had communication difficulties with their doctor (RR=1.22, 95%CI 1.05-1.43), iii) 282 
felt their doctor was not listening or did not understand their condition (RR=1.14, 95%CI  283 
1.00-1.31), iv) felt their doctor knew little about pain (RR=1.20, 95%CI 1.02-1.42), v) were 284 
afraid they might become dependent on opioids (RR=1.13, 95%CI 1.01-1.26), vi) were 285 
unable to access specialists (RR=1.17, 95%CI 1.01-1.35), and vii) were unable to afford 286 
medication (RR=1.22, 95%CI 1.01-1.46).  287 
 288 
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Medication Beliefs, Pain Self-Efficacy, Social Support and Alcohol and other Drug Use  289 
In regards to medication beliefs, the ‘Outer Regional/Remote group’ scored significantly 290 
higher on the Specific-Concerns BMQ subscale compared to the ‘Major City group’ however 291 
this association was not statistically significant following adjustment for covariates (Table 3). 292 
The ‘Inner Regional group’ scored higher on PSEQ and MOS Social Support score 293 
(indicating greater pain self-efficacy and social support) as compared to the ‘Major City 294 
group’; these associations remained statistically significant in multivariate analyses. Notably, 295 
the ‘Outer Regional/Remote group’ also reported higher mean PSEQ scores compared to the 296 
‘Major City group’ following adjustment for covariates. The ‘Inner Regional group’ reported 297 
a greater relative risk of weekly or more frequent alcohol use in the past year, and the ‘Outer 298 
Regional/Remote group’ reported a greater relative risk of weekly or more frequent cannabis 299 
use, as compared to the ‘Major City group’; these associations were not statistically 300 
significant in multivariate analyses.  301 
***Table 3 approximately here*** 302 
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Discussion 303 
Considerable effort has been dedicated to improving health care access for Australians in 304 
regional and remote areas, including the National Strategic Framework for Rural and Remote 305 
Health (35). This study represents the first detailed examination of remoteness differences in 306 
access and barriers to health service use for chronic pain in Australia, a critical undertaking 307 
given the increasing prevalence of CNCP and associated health care burden (2).  308 
 309 
In regards to demographic and clinical profile, the ‘Inner Regional group’ and ‘Outer 310 
Regional/Remote group’ were more likely to be male and have no private health insurance 311 
than the ‘Major City group’; the latter group was also younger than the ‘Major City group’. 312 
These findings align with national data showing that private health insurance (i.e., additional 313 
healthcare cover to that provided by the Australian government Medicare scheme which is 314 
paid for by the individual) is less common amongst residents of high socio-economic 315 
disadvantage areas (as generally typified in regional and remote areas), with expense cited as 316 
the primary barrier (36). Literature points to greater disadvantage in regional and remote 317 
areas, evident via lower incomes (although this finding was not evident in the present study), 318 
higher unemployment rates, and shorter life expectancies (16, 37). While the number of 319 
people in the current study reporting low income and unemployment did not vary by 320 
geographical remoteness, these indicators of disadvantage were considerably higher in this 321 
sample overall than reported in the general population (38, 39). Similarly, poor mental and 322 
physical health outcomes were elevated overall but generally did not differ significantly 323 
across the remoteness groups (with the exception of better mental health outcomes for the 324 
‘Inner Regional group’ relative to the ‘Major City group’). These findings suggest that 325 
people with CNCP as a group may be characteristed by poorer socio-economic, mental and 326 
physical wellbeing.  327 
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In regards to treatment, the ‘Inner Regional group’ were more likely to be prescribed fentanyl 329 
and less likely to be prescribed oxycodone and prescription codeine, and the ‘Outer 330 
Regional/Remote group’ were more likely to be prescribed morphine, compared to the 331 
‘Major City group’ though, despite the difference in prescribing patterns, no difference in 332 
dose (represented as OME) was detected. Health service access generally did not differ 333 
between the remoteness groups and perceived barriers to health service access were similar 334 
for the ‘Major City group’ and ‘Inner Regional group’ (although the latter reported greater 335 
pain self-efficacy and social support). In contrast, the ‘Outer Regional/Remote group’ were 336 
more likely to report communication problems and lack of confidence in their doctor in 337 
treating CNCP, difficulties accessing specialists, and difficulties affording opioid medication 338 
(as well as higher pain self-efficacy), relative to both groups.  339 
 340 
These perceived barriers reflect those reported in a study of people with chronic low back 341 
pain in rural Western Australia, with patients citing poor access to information and sevices 342 
and inadequate pain management training for local practitioners (18). Several population-343 
based studies have shown similar rates of health service access across urban and rural areas 344 
with certain exceptions, including poorer specialist access in remote areas (17, 40-42). 345 
Indeed, a systematic survey of 57 Australian services providing outpatient care for persistent 346 
pain showed lower provision of pain specialist services for remote patients (14). However, it 347 
important to note that these studies were conducted prior to, or initially following, 348 
introduction of Australia’s National Pain Strategy (NPS). The NPS details strategic actions to 349 
improve access to information and services, with an emphasis on skilled professionals, 350 
evidence-based care, and interdisciplinary pain management (15, 43). Since then, a number of 351 
initiatives have been implemented (43), including state-based pain management plans in New 352 
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South Wales and Queensland, the Australian Government Medicare-based telehealth program 353 
(i.e., support for patient-specialist video consultations), and 14 new regional pain centres (43, 354 
44). Particular emphasis has been placed on training for general practitioners (45) in regional 355 
and remote areas given that approximately one-fifth of patients seen in general practice report 356 
chronic pain (46). While these endeavours must be acknowledged, the present results indicate 357 
that continued efforts are required to address geographic inequality in treatment given the 358 
perceived barriers reported by our participants. Indeed, preliminary evidence that certain pain 359 
education programs for general health care providers (47) and patients (48) in remote areas in 360 
Australia enhance practitioner skills, reduce waitlists, and decrease treatment costs is 361 
promising for addressing patient-practitioner communication problems and patient 362 
confidence in pain treatment.  363 
 364 
Strengths and Limitations 365 
The POINT cohort comprises the largest sample of people with CNCP interviewed in 366 
Australia, with a wealth of data regarding a range of domains, particularly physical and 367 
mental health, treatment, and health service access (19). Cohort participants were receiving 368 
opioid therapy and recruited through pharmacies; thus, some similiarities in health care 369 
access and perception of barriers across geographic area are to be expected in the present 370 
study. This sample may not be representative of all people who are prescribed opioids for 371 
CNCP. It may be that those people with barriers so significant that they cannot even access a 372 
prescriber and/or pharmacy may not have been represented in this cohort. However, we have 373 
previously compared key characteristics (gender, age and type of opioid) of those enrolled in 374 
the study with the characteristics of all customers recorded as purchasing opioids in a random 375 
sample of 71 recruiting pharmacies and found striking similarities (49). Specifically, 52% 376 
were female (the POINT cohort was 55% female); and 7% were 18-34 years, 55% 35-64 377 
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years and 38% 65+ years (vs. 5%, 62% and 33% respectively, in the POINT cohort). Of these 378 
customers, 63% were prescribed oxycodone (vs. 62% in the POINT sample), 16.5% 379 
prescribed morphine (vs. 15% in the POINT cohort), 21% prescribed fentanyl patches (vs. 380 
15% in the POINT cohort) and 24% prescribed buprenorphine patches (vs. 21% in the 381 
POINT cohort). Although it is not possible to determine whether all the opioid customers 382 
recorded by these pharmacists had been taking these opioids for chronic pain, and for six 383 
weeks or more, the similarities are reassuring. It should be noted a similar geographical 384 
breakdown was evident for those participants who were excluded who had provided a 385 
postcode (‘major cities’: 51%; inner regional: 36%; outer regional: 13%) to the final sample 386 
used in the present study. It should be noted that those participants excluded due to not 387 
completing core measures relevant to this study were more likely to be male (51% versus 388 
43%, respectively) and younger (M=53.6 years, SD=13.5 versus M=58.4 years, SD=13.5) 389 
than the final cohort. There are potential biases in self-report, although self-report is generally 390 
reliable when there are no disincentives for being honest (50), and participants have been 391 
assured of anonymity and confidentiality (as was the case in this study). The percentage of 392 
the POINT cohort who reside in outer regional/remote areas is similar to that evident in the 393 
general population (14% versus 11%, respectively) (32). However, given the number of 394 
participants within the ‘Outer Regional/Remote group’, we would encourage consideration of 395 
the effect size alongside statistical significance for comparisons involving this group given 396 
reduced statistical power, and caution in drawing inferences from these analyses.  397 
 398 
Conclusion 399 
Despite similar self-reported rates of health service access, participants in outer regional and 400 
remote areas were more likely to cite communication problems and lack of confidence in 401 
their doctor in treating CNCP, difficulties accessing specialists, and difficulties affording 402 
Geography, Healthcare and Chronic Pain 
opioid medication. In order to achieve “knowledgeable, empowered, and supported 403 
consumers” of services (Goal 2 of the Australian National Pain Strategy; 15), future strategies 404 
must be focused on enhancing the patient experience of treatment and maximising skills and 405 
knowledge training amongst health care providers, with a focus on strategies targeted for 406 
regional and remote locations.   407 
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Table 1 
Demographic and Clinical Characteristics of People with CNCP According to Geographical Remoteness 
Outcomea 
 
Total 
Sample 
(n=1,235) 
(A) 
Major City 
group 
n=608 
(B)  
Inner Regional 
Group 
n=627 
 
(C) 
Outer Regional/Remote 
group 
n=176 
 
B vs A (ref) b 
 
C vs A (ref) b 
 
% 
(95% CI)
% 
(95% CI)
% 
(95% CI)
% 
(95% CI) 
RRR (95% CI) 
p value 
RRR (95% CI) 
p value 
Demographics:       
Age (M, IQR) 59 (49-68) 59 (48-69) 60 (50-68) 57 (47-65) 1.01 (1.00-1.01), p=.289 0.98 (0.97-1.00), p=.014 
Male 43 (40-46) 39 (35-42) 46 (42-51) 50 (43-57) 1.38 (1.08-1.77), p=.010 1.60 (1.14-2.24), p=.006 
Not completed tertiary education 64 (61-67) 61 (57-64) 69 (64-73) 64 (56-70) 1.43 (1.11-1.85), p=.006 1.14 (0.81-1.62), p=.456 
Unemployed 47 (44-50) 48 (44-520 43 (38-47) 52 (44-59) 0.79 (0.62-1.01), p=.062 1.14 (0.82-1.60), p=.434 
Weekly income <AUD$400 59 (56-62) 57 (53-61) 62 (34-43) 59 (52-65) 1.24 (0.97-1.59), p=.090 1.08 (0.77-1.52), p=.646 
Do not have private health 
insurance 
63 (60-66) 58 (54-62) 68 (63-72) 69 (62-76) 1.53 (1.19-1.97), p=.001 1.65 (1.16-2.37), p=.006 
Pain Condition:       
Duration of living in pain 
(months; M, IQR) 
120 (60-
252) 
120 (48-264) 144 (60-276) 120 (60-204) 1.00 (1.00-1.00), p=0.573 1.00 (1.00-1.00), p=.870 
CNCP conditions (lifetime):       
Chronic back/neck problems 69 (77-82) 80 (77-83) 79 (75-83) 77 (71-83) 0.94 (0.70-1.28), p=.707 0.85 (0.56-1.27), p=.414 
Arthritis/ rheumatism 68 (66-71) 68 (64-71) 71 (66-75) 64 (56-70) 1.14 (0.87-1.48), p=.340 0.83 (0.59-1.18), p=.306 
Frequent/severe headaches 45 (42-48) 46 (42-50) 43 (38-47) 46 (39-53) 0.89 (0.70-1.14), p=.343 1.01 (0.72-1.42), p=.944 
Visceral pain 31 (29-34) 32 (28-36) 32 (28-36) 29 (23-36) 0.99 (0.76-1.29), p=.945 0.87 (0.60-1.26), p=.460 
Brief Pain Inventory (BPI): 
Severity score (M, SD) 
5.0 (1.8) 5.2 (1.8) 4.9 (1.8) 5.0 (1.7) 0.92 (0.86-0.98), p=.012 0.96 (0.87-1.05), p=.329 
Brief Pain Inventory (BPI): 
Interference score (M, SD) 
5.9 (2.3) 5.7 (2.3) 5.4 (2.3) 5.7 (2.2) 0.95 (0.91-1.01), p=.088 1.00 (0.92-1.07), p=.900 
Health:       
Short Form Health Survey (SF-
12): Mental Health score (M, SD)  
44.3 (33.2-
54.7) 
41.8 (32.0-
54.0) 
46.9 (35.0-55.7) 45.4 (34.7-54.6) 1.02 (1.01-1.03), p=.002 1.01 (1.00-1.02), p=.160 
Short Form Health Survey (SF-
12):  Physical Health score (M, 
26.5 (22.3-
31.3) 
26.2 (21.9-
30.8) 
26.7 (22.7-31.4) 26.4 (23.1-32.07) 1.01 (0.99-1.03), p=.201 1.01 (0.99-1.03), p=.413 
SD) 
Depression (PHQ-9 score ≥10)  44 (42-47) 48 (44-52) 40 (35-44) 44 (37-52) 0.71 (0.55-0.90), p=.006 0.86 (0.61-1.20), p=.376 
Anxiety (GAD-7 score ≥10) ^ 22 (20-24) 23 (20-27) 17 (14-21) 27 (21-34) 0.69 (0.50-0.95), p=.021 1.24 (0.84-1.82), p=.279 
PTSD (Primary Care PTSD 
Screen score ≥3)  
14 (13-16) 16 (13-19) 12 (9-15) 15 (11-21) 0.73 (0.51-1.04), p=.079 0.97 (0.61-1.54), p=.885 
Medication Use:       
Median OME daily dose (mg; M, 
IQR)  
73 (36-144) 76 (36-150) 68 (35-126) 66 (31-144) 1.00 (1.00-1.00), p=.124 1.00 (1.00-1.00), p=.793 
OME daily dose >200mg^ 15 (13-17) 16 (13-19) 12 (10-16) 19 (14-26) 0.75 (0.52-1.10), p=.137 1.25 (0.79-1.98), p=.349 
Duration continuous opioid 
medication  (months; M, IQR) 
48 (18-120) 48 (24-120) 48 (16-120) 60 (40-132) 1.01 (1.00-1.00), p=.317 1.01 (1.00-1.00), p=.216 
Current prescribed 
opioid medication:   
      
Oxycodone 60 (57-63) 63 (59-67) 56 (52-61) 60 (52-67) 0.76 (0.60-0.98), p=.033 0.88 (0.62-1.23), p=.445 
Morphine 15 (14-18) 16 (13-19) 12 (10-16) 22 (17-29) 0.74 (0.52-1.06), p=.099 1.52 (1.00-2.30), p=.049 
Buprenorphine 23 (20-25) 21 (18-25) 25 (21-29) 22 (16-28) 1.24 (0.93-1.66), p=.142 1.02 (0.68-1.54), p=.915 
Methadone 4 (3-5) 4 (3-6) 4 (2-6) 6 (3-10) 0.94 (0.49-1.79), p=.841 1.53 (0.72-3.28), p=.269 
Fentanyl 14 (13-17) 13 (10-15) 18 (15-22) 13 (8-18) 1.51 (1.07-2.12), p=.018 1.00 (0.60-1.66), p>.999 
Tramadol 10 (8-11) 10 (8-13) 8 (6-11) 11 (8-17) 0.73 (0.47-1.12), p=.150 1.11 (0.65-1.89), p=.704 
Hydromorphone 4 (3-5) 4 (3-6) 4 (2-6) 3 (1-7) 1.00 (0.53-1.89), p=.991 0.74 (0.28-1.99), p=.555 
Prescription codeine 23 (21-26) 26 (22-29) 19 (16-23) 25 (19-32) 0.70 (0.52-0.94), p=.018 0.97 (0.66-1.43), p=.895 
Note. ^48 participants had missing data for GAD-7 and only 1094 participants provided data to calculate OME. OME: oral morphine equivalent. 
PHQ-9: Patient Health Questionnaire; GAD-7: Generalised Anxiety Disorder scale; PTSD: post-traumatic stress disorder; RRR: relative risk 
ratio; 95% CI: 95% confidence interval; M, IQR: median and IQR: interquartile range; M, SD: mean and standard deviation. Bolded values 
indicate statistical significance (p<.050); italicised variables indicate trend towards statistical significance (p<.100).  
Table 2 
Health Service Access and Perceived Barriers to Access for People with CNCP According to Geographical Remoteness 
Outcome 
Total 
Sample 
n=1,235 
(A) 
Major 
City 
group 
n=608 
(B)  
Inner 
Regional 
group 
n=451 
 
(C) 
Outer 
Regional/Remote 
group 
n=176 
 
B vs A (ref)  C vs A (ref)  B vs A (ref)  C vs A (ref)  
% 
(95% 
CI) 
% 
(95% 
CI)
% 
(95% CI) 
% 
(95% CI) 
RRR  
(95% CI) 
p value 
RRR  
(95% CI) 
p value
Adjusted RRR  
(95% CI) 
p value
Adjusted RRR  
(95% CI) 
p value 
Service Use (past 
month) 
        
General Practitioner 95 (94-
96) 
96 (95-
98) 94 (92-96) 94 (89-97) 
0.61 (0.34-1.09), 
p=.097 
0.56 (0.27-1.19), 
p=.130 
0.66 (0.36-1.21), 
p=.178 
0.55 (0.26-1.17), 
p=.121 
Number of visits 
amongst those who 
had accessed GP 
(M, IQR) 
2 (1-3) 2 (1-3) 2 (1-2) 2 (1-3) 0.97 (0.89-1.05), p=.391 
1.01 (0.91-1.11), 
p=.879 
0.99 (0.91-1.07), 
p=.713 
1.00 (0.91-1.11), 
p=.941 
Ambulance 7 (5-8) 7 (5-10) 7 (5-9) 5 (3-9) 0.89 (0.55-1.44), p=.622 
0.69 (0.33-1.44), 
p=.326 
0.86 (0.52-1.44), 
p=.577 
0.71 (0.34-1.51), 
p=.712 
Emergency 
Department 
12 (10-
14) 11 (9-14) 13 (10-16) 14 (9-20) 
1.17 (0.81-1.71), 
p=.403 
1.28 (0.77-2.10), 
p=.341 
1.11 (0.75-1.64), 
p=.606 
1.16 (0.69-1.94), 
p=.571 
Day Procedure 11 (9-13) 12 (10-15) 9 (7-12) 9 (6-14) 
0.70 (0.46-1.04), 
p=.078 
0.71 (0.40-1.25), 
p=.238 
0.70 (0.46-1.06), 
p=.090 
0.75 (0.42-1.33), 
p=.324 
Physiotherapy # 16 (14-
18) 
17 (15-
21) 13 (10-16) 19 (14-26) 
0.69 (0.49-0.98), 
p=.035 
1.13 (0.74-1.74), 
p=.566 
0.83 (0.57-1.19), 
p=.308 
1.39 (0.89-2.17), 
p=.155 
Mental Health 
Services# 11 (9-13) 
13 (10-
15) 9 (6-12) 10 (7-16) 
0.66 (0.44-1.00), 
p=.046 
0.80 (0.46-1.37), 
p=.414 
0.74 (0.48-1.14), 
p=.172 
0.70 (0.39-1.23), 
p=.213 
Specialist Services# 14 (12-
16) 
17 (14-
20) 12 (10-16) 12 (8-18) 
0.71 (0.50-1.02), 
p=.059 
0.68 (0.41-1.26), 
p=.131 
0.81 (0.56-1.18), 
p=.273 
0.73 (0.43-1.22), 
p=.225 
Physical Therapies# 8 (7-10) 5 (4-8) 9 (6-12) 15 (10-21) 1.65 (1.02-2.67), 
p=.041 
3.02 (1.75-5.21), 
p<.001 
1.66 (1.02-2.70), 
p=.042 
2.92 (1.67-5.08), 
p<.001 
Complementary and 42 (39- 42 (38- 41 (36-45) 40 (33-48) 0.94 (0.74-1.21), 0.92 (0.66-1.30), 0.98 (0.76-1.27), 0.96 (0.67-1.37), 
Alternative Therapies# 44) 46) p=.631 p=.648 p=.885 p=.960 
Barriers to Access         
Felt your doctor was 
not confident in 
prescribing drugs for 
pain treatment 
19 (17-
21) 
18 (15-
22) 
16 (13-20) 28 (21-35) 0.86 (0.62-1.20), 
p=.379 
1.71 (1.15-2.54), 
p=.008 
0.96 (0.58-1.36), 
p=.816 
1.73 (1.14-2.62), 
p=.009 
Experienced 
communication 
problems with your 
doctor 
19 (16-
21) 
19 (16-
22) 
15 (12-19) 25 (20-32) 0.79 (0.57-1.09), 
p=.152 
1.48 (0.99-2.20), 
p=.055 
0.87 (0.61-1.23), 
p=.427 
1.47 (0.96-2.23), 
p=.075 
Felt your doctor was 
not 
listening/understanding 
20 (18-
22) 
19 (16-
22) 
19 (15-22) 26 (20-33) 0.98 (0.72-1.35), 
p=.913 
1.53 (1.03-2.28), 
p=.036 
1.12 (0.80-1.56), 
p=.518 
1.57 (1.03-2.37), 
p=.035 
Felt your doctor knew 
little about pain 
15 (13-
17) 
15 (12-
18) 
13 (10-16) 21 (16-28) 0.84 (0.59-1.19), 
p=.322 
1.49 (0.97-2.29), 
p=.069 
0.98 (0.67-1.42), 
p=.902 
1.56 (0.99-2.45), 
p=.055 
Fear you may become 
dependent on drugs 
37 (35-
40) 
40 (36-
44) 
32 (28-36) 42 (34-49) 0.71 (0.55-0.91), 
p=.008 
1.07 (0.76-1.51), 
p=.697 
0.79 (0.60-1.03), 
p=.081 
1.12 (0.78-1.60), 
p=.536 
Felt your doctor would 
consider your drug-
seeking 
11 (9-13) 11 (9-14) 9 (7-12) 15 (10-21) 0.78 (0.52-1.18), 
p=.241 
1.33 (0.81-2.17), 
p=.263 
0.88 (0.57-1.35), 
p=.543 
1.28 (0.76-2.14), 
p=.357 
Unable to get to a 
pharmacy or doctor  
15 (13-
17) 
15 (13-
18) 
13 (10-16) 18 (13-25) 0.81 (0.57-1.16), 
p=.256 
1.25 (0.80-1.95), 
p=.334 
0.94 (0.64-1.39), 
p=.759 
1.16 (0.72-1.88), 
p=.548 
Unable to access 
specialist advice  
19 (16-
21) 
18 (15-
21) 
17 (14-21) 26 (20-33) 0.97 (0.71-1.35), 
p=.872 
1.62 (1.08-2.42), 
p=.019
1.10 (0.77-1.55), 
p=.606  
1.56 (1.01-2.39), 
p=.044 
Unable to afford opioid 
medication 
12 (11-
14) 
12 (10-
15) 
11 (8-14) 18 (13-24) 0.87 (0.59-1.29), 
p=.498 
1.61 (1.01-2.55), 
p=.044 
0.90 (0.60-1.35), 
p=.613 
1.40 (0.87-2.28), 
p=.170 
Unable to afford other 
types of medication  
21 (19-
23) 
21 (18-
25) 
19 (15-23) 26 (20-33) 0.84 (0.62-1.14), 
p=.267 
1.26 (0.85-1.87), 
p=.247 
0.86 (0.62-1.19), 
p=.354 
1.11 (0.73-1.67), 
p=.639 
Unable to afford other 
treatments  
(e.g., counselling, 
physiotherapy)  
41 (38-
43) 
40 (37-
45) 
40 (36-45) 42 (35-49) 0.99 (0.77-1.27), 
p=.942 
1.06 (0.75-1.50), 
p=.749 
1.06 (0.80-1.39), 
p=.703 
0.95 (0.65-1.38), 
p=.783 
Note. Adjusted analyses (AOR) control for age, sex, current private health insurance, income<$400AUD, tertiary education, and BPI pain 
severity score. # Note that this data refers only to use of services specifically for pain treatment.  RRR: relative risk ratio; 95% CI: 95% 
confidence interval; M: median; IQR: interquartile range. Bolded values indicate statistical significance (p<.050).  
Table 3 
Medication Beliefs, Pain Self-Efficacy, Social Support and Alcohol and other Drug Use According to Geographical Remoteness 
Outcomea 
Total Sample 
n=1,235 
(A) 
Major City 
group 
n=608 
(B)  
Inner 
Regional 
group 
n=451 
 
(C) 
Outer 
Regional/Rem
ote group 
n=176 
 
B vs A (ref)  
 
C vs A (ref)  
 
B vs A (ref)  
 
C vs A (ref) 
 
% 
(95% CI) 
% 
(95% CI) 
% 
(95% CI) 
% 
(95% CI) RRR (95% 
CI) 
p value 
RRR (95% 
CI) 
p value 
Adjusted 
RRR (95% 
CI) 
p value 
Adjusted 
RRR (95% 
CI) 
p value 
Medication Beliefs:         
Medication Beliefs: 
Specific-Necessity (M, SD) 
19.8 (3.8) 19.5 (3.8) 19.8 (3.8) 20.1 (3.5) 1.02 (0.98-
1.07), p=.374 
1.04 (0.98-
1.10), p=.189 
1.01 (0.97-
1.06), p=.647 
1.04 (0.98-
1.11), p=.173 
Medication Beliefs: 
Specific-Concerns (M, SD) 
14.2 (4.3) 13.8 (4.2) 14.2 (4.5) 14.8 (4.1) 1.02 (0.98-
1.06), p=.253 
1.05 (1.00-
1.11), p=.039 
1.03 (0.98-
1.07), p=.231 
1.05 (1.00-
1.11), p=.061 
Coping and Support:         
Pain Self Efficacy 
Questionnaire (PSEQ) score 
(M, SD) 
29.9 (13.4) 28.5 (13.5) 31.5 (13.1) 30.2 (13.6) 1.02 (1.01-
1.03), p=.001 
1.01 (1.00-
1.02), p=.153 
1.02 (1.01-
1.03), p=.001 
1.02 (1.00-
1.03), p=.025 
Medical Outcomes Survey 
(MOS) Social Support score 
(M, SD)  
3.3 (1.1) 3.2 (1.1) 3.3 (1.1) 3.3 (1.1) 1.12 (1.01-
1.26), p=.041 
1.08 (0.93-
1.26), p=.335 
1.13 (1.00-
1.27), p=.044 
1.12 (0.96-
1.32), p=.155 
Alcohol and Drug Use:         
Used alcohol weekly or 
more frequent (past 12 
month) 
29 (27-32) 27 (23-30) 33 (29-37) 29 (23-36) 1.34 (1.02-
1.75), p=.033 
1.11 (0.77-
1.62), p=.579 
1.33 (1.00-
1.76), p=.051 
1.14 (0.77-
1.68), p=.522 
Used tobacco daily or more 
frequently (past 12 months 
31 (28-33) 31 (28-35) 28 (24-33) 33 (27-41) 0.86 (0.65-
1.12), p=.251 
1.09 (0.76-
1.56), p=.630 
0.76 (0.56-
1.03), p=.079 
0.79 (0.53-
1.18), p=.253 
month) 
Used cannabis weekly or 
more frequently (past 12 
months) 
6 (5-8) 6 (4-8) 5 (3-7) 10 (7-16) 0.78 (0.45-
1.35), p=.372 
1.81 (1.00-
3.28), p=.049 
0.62 (0.35-
1.11), p=.104 
1.19 (0.64-
2.23), p=.589 
Note. Adjusted analyses (AOR) control for age, sex, current private health insurance, income<$400AUD, tertiary education, and BPI pain 
severity score. RRR: relative risk ratio; 95% CI: 95% confidence interval; M, SD: mean and standard deviation. Bolded values indicate statistical 
significance (p<.050).  
 
